VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases 3 years ago [#item_full_content] VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network OpenDateOctober 13, 2021In relation toSimilar postFDA Approves VBI Vaccines’ 3-Antigen Hepatitis B VaccineDateDecember 1, 2021In relation toSimilar postVBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B VaccineDateJuly 1, 2021In relation toSimilar post